Structure‐Based Virtual Screening for Dopamine D2 Receptor Ligands as Potential Antipsychotics
暂无分享,去创建一个
Peter Kolb | Antti Poso | Agnieszka A Kaczor | A. Poso | P. Kolb | M. Loza | A. Kaczor | María I Loza | Andrea G Silva | Marián Castro | M. Castro
[1] Andreas Evers,et al. Virtual screening of biogenic amine-binding G-protein coupled receptors: comparative evaluation of protein- and ligand-based virtual screening protocols. , 2005, Journal of medicinal chemistry.
[2] P. Conn,et al. Emerging approaches for treatment of schizophrenia: modulation of cholinergic signaling. , 2012, Discovery medicine.
[3] Brian K Shoichet,et al. Structure-based drug screening for G-protein-coupled receptors. , 2012, Trends in pharmacological sciences.
[4] Mark A. Murcko,et al. Virtual screening : an overview , 1998 .
[5] Chris de Graaf,et al. Structure-Based Prediction of G-Protein-Coupled Receptor Ligand Function: A β-Adrenoceptor Case Study , 2015, J. Chem. Inf. Model..
[6] J. Baell,et al. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.
[7] J. Soares,et al. Atypical antipsychotics and mood stabilization in bipolar disorder , 2003, Psychopharmacology.
[8] P. Robledo,et al. QF2004B, a potential antipsychotic butyrophenone derivative with similar pharmacological properties to clozapine , 2006, Neuropharmacology.
[9] Shaomeng Wang,et al. Tranylcypromine Substituted cis-Hydroxycyclobutylnaphthamides as Potent and Selective Dopamine D3 Receptor Antagonists , 2014, Journal of medicinal chemistry.
[10] H. Hartung,et al. Mitoxantrone (Novantrone®) in multiple sclerosis: new insights , 2004, Expert review of neurotherapeutics.
[11] M. Rowley,et al. Current and novel approaches to the drug treatment of schizophrenia. , 2001, Journal of medicinal chemistry.
[12] Marcin Feder,et al. Ligand-Optimized Homology Models of D1 and D2 Dopamine Receptors: Application for Virtual Screening , 2013, J. Chem. Inf. Model..
[13] W. Patrick Walters,et al. A guide to drug discovery: Designing screens: how to make your hits a hit , 2003, Nature Reviews Drug Discovery.
[14] Ryan G. Coleman,et al. ZINC: A Free Tool to Discover Chemistry for Biology , 2012, J. Chem. Inf. Model..
[15] S. Leucht,et al. Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective , 2014, Evidence-Based Mental Health.
[16] A. Taly. Novel approaches to drug design for the treatment of schizophrenia , 2013, Expert opinion on drug discovery.
[17] Yi-Ping Phoebe Chen,et al. A steered molecular dynamics mediated hit discovery for histone deacetylases. , 2014, Physical chemistry chemical physics : PCCP.
[18] H. Meltzer. Update on typical and atypical antipsychotic drugs. , 2013, Annual review of medicine.
[19] F. Sanz,et al. Novel insights on the structural determinants of clozapine and olanzapine multi-target binding profiles. , 2014, European journal of medicinal chemistry.
[20] H. Stark,et al. Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics. , 2009, Bioorganic & medicinal chemistry letters.
[21] G. Schneider,et al. From Virtual to Real Screening for D3 Dopamine Receptor Ligands , 2005, Chembiochem : a European journal of chemical biology.
[22] Peter Kolb,et al. Limits of Ligand Selectivity from Docking to Models: In Silico Screening for A1 Adenosine Receptor Antagonists , 2012, PloS one.
[23] B. Roth,et al. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia , 2004, Nature Reviews Drug Discovery.
[24] T. Suppes,et al. Treatment of bipolar mania with atypical antipsychotics , 2004, Expert review of neurotherapeutics.
[25] Mercedes K. Taylor,et al. Discovery, Optimization, and Characterization of Novel D2 Dopamine Receptor Selective Antagonists , 2014, Journal of medicinal chemistry.
[26] Chunyan Tan,et al. A Two-Step Target Binding and Selectivity Support Vector Machines Approach for Virtual Screening of Dopamine Receptor Subtype-Selective Ligands , 2012, PloS one.
[27] H. Senderowitz,et al. G Protein-Coupled Receptors: target-based in silico screening. , 2009, Current pharmaceutical design.
[28] Michael M. Mysinger,et al. Structure-based ligand discovery for the protein–protein interface of chemokine receptor CXCR4 , 2012, Proceedings of the National Academy of Sciences.
[29] Avner Schlessinger,et al. Ligand Discovery from a Dopamine D3 Receptor Homology Model and Crystal Structure , 2011, Nature chemical biology.
[30] F. López-Muñoz,et al. Neurobiological Background for the Development of New Drugs in Schizophrenia , 2011, Clinical neuropharmacology.
[31] Y. Cheng,et al. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.
[32] Subramaniam Ananthan,et al. Recent Advances in Structure-Based Virtual Screening of G-Protein Coupled Receptors , 2009, The AAPS Journal.
[33] Sarah A. Scott,et al. Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificity. , 2009, Bioorganic & medicinal chemistry letters.
[34] Brian K. Shoichet,et al. Structure-Based Discovery of A2A Adenosine Receptor Ligands , 2010, Journal of medicinal chemistry.
[35] Chris de Graaf,et al. From heptahelical bundle to hits from the Haystack: structure-based virtual screening for GPCR ligands. , 2013, Methods in enzymology.
[36] B. Roth,et al. Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one. , 2008, Bioorganic & medicinal chemistry.
[37] A. Sali,et al. Statistical potential for assessment and prediction of protein structures , 2006, Protein science : a publication of the Protein Society.
[38] Ruben Abagyan,et al. Structure-Based Ligand Discovery Targeting Orthosteric and Allosteric Pockets of Dopamine Receptors , 2013, Molecular Pharmacology.
[39] S. Salomone,et al. Homology Modeling of Dopamine D2 and D3 Receptors: Molecular Dynamics Refinement and Docking Evaluation , 2012, PloS one.
[40] Peter Kolb,et al. Identifying modulators of CXC receptors 3 and 4 with tailored selectivity using multi-target docking. , 2015, ACS chemical biology.
[41] Markus Lill,et al. Virtual screening in drug design. , 2013, Methods in molecular biology.
[42] John P. Overington,et al. ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..
[43] R. Stevens,et al. Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor. , 2011, Journal of medicinal chemistry.
[44] Jonathan A. Javitch,et al. Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist , 2010, Science.
[45] Ferran Sanz,et al. New serotonin 5-HT(2A), 5-HT(2B), and 5-HT(2C) receptor antagonists: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo and heterocycloalkanones. , 2002, Journal of medicinal chemistry.
[46] R. Friesner,et al. Novel procedure for modeling ligand/receptor induced fit effects. , 2006, Journal of medicinal chemistry.